Triple Antithrombotic Therapy After Coronary Stenting
Why Expert Opinion Is Necessary

Freek W.A. Verheugt, MD, FACC, FESC

Dual antiplatelet therapy has become the cornerstone of the treatment of patients undergoing coronary stenting and of those with acute coronary syndromes with or without stent implantation. Although there is consensus about the indication for dual antiplatelet therapy, there is little evidence about the optimal duration of therapy. In patients surviving non–ST-segment elevation–acute coronary syndromes, 1 year of treatment is advised. Intuitively, cardiologists prefer longer dual antiplatelet therapy rather than single antiplatelet medication (aspirin alone) in patients with drug-eluting stents when compared with carriers of bare metal stents. Consequently, many patients in the cardiology practice in 2011 are on dual antiplatelet therapy, mainly aspirin and clopidogrel. The only important side effect of dual antiplatelet therapy is increased bleeding in comparison to aspirin alone. This has been established in the large trials with clopidogrel in acute coronary syndromes as well as in atrial fibrillation. Especially in the latter, dual antiplatelet therapy has been shown to be as hazardous as oral anticoagulation. Special attention of the risks of dual antiplatelet therapy has been given to patients awaiting coronary artery bypass surgery. Clopidogrel on top of aspirin has been associated with significantly increased blood loss during coronary surgery when compared with aspirin alone. However, this excess bleeding was not significantly associated with an increased risk of reoperation or mortality. Yet, it is generally advised to discontinue clopidogrel 5 days ahead of coronary surgery. Little is known, however, about the optimal strategy in patients on dual antiplatelet therapy undergoing other forms of surgery such as abdominal surgery, orthopedic procedures, neurosurgical operations, or procedures in other vital organs in which bleeding can result in organ loss. Yet, the most vexing problem in this field is the use of comparison-dual antiplatelet therapy in patients on oral anticoagulation, usually for long-term stroke prevention in atrial fibrillation. Bleeding is considered the most important side effect and has been shown to be increased, with 43% in the RE-LY trial to 80% in a large Danish registry, when aspirin is combined with warfarin for atrial fibrillation. For dual antiplatelet therapy, the increase is 370%.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.

Correspondence to Freek W.A. Verheugt, MD, FACC, FAHA, FESC, Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, NL-1091-AC Amsterdam, The Netherlands. E-mail f.w.a.verheugt@olvg.nl

(Circ Cardiovasc Interv. 2011;4:410-412.)

© 2011 American Heart Association, Inc.

Circ Cardiovasc Interv is available at http://circinterventions.ahajournals.org

DOI: 10.1161/CIRCINTERVENTIONS.111.965210
the Europeans do so for 3 months for the modern limus stents and 6 months for the paclitaxel stents.

Future Perspectives
Unfortunately, randomized, controlled trials on the optimal antithrombotic protection are lacking. Currently, 3 randomized trials are running on the risks and benefits of triple antithrombotic therapy (aspirin, clopidogrel, and warfarin) versus “safer” antithrombotic therapy in anticoagulated patients after coronary stent implantation. One of these studies is initiated from the Netherlands (WOEST),18 1 in Germany (ISAR-TRIPLE),19 and 1 in Spain (MUSICA-2). The outcomes of these trials will guide the treatment of this difficult group of patients. Especially, the absence of aspirin in 1 arm of WOEST is provocative, as well as the short 6-week run of clopidogrel in 1 arm of ISAR-TRIPLE and the interruption of warfarin in MUSICA-2.

The New Agents
The novel antiplatelet drugs prasugrel and ticagrelor are more effective than clopidogrel in patients with a high thrombotic risk such as acute coronary syndromes in preventing recurrent ischemic events, but in the setting coronary stenting are certainly not associated with less bleeding.20,21 Thus, the views on both sides of the ocean on the warfarin issue will not be influenced by the use of these agents. On the contrary, the duration (and/or dosing) of antiplatelet therapy may be lowered to minimize the extra bleeding hazard.

Different thoughts can be given to the novel anticoagulants.22,23 They look certainly safer than warfarin, especially with respect to intracranial hemorrhage. This opens new opportunities for patients with a high bleeding risk such as those on triple therapy after stenting. The only data so far, albeit post hoc and not randomized, comes from the RE-LY trial with dabigatran.24 Antiplatelet therapy increased bleeding by 60%, irrespective of the anticoagulant used (warfarin, dabigatran 110 mg twice daily, or dabigatran 150 mg twice daily). The reduced risk of bleeding of dabigatran was maintained in the presence of concomitant antiplatelet therapy. The lowest rate of intracranial hemorrhage in combination with antiplatelet drugs was seen with the lower dose of dabigatran, even lower than with warfarin alone in the absence of antiplatelet agents. Whether low-dose dabigatran is the preferred anticoagulant when anticoagulation must be combined with antiplatelet drugs should be tested in a new randomized, controlled trial against warfarin in aspirin (plus clopidogrel)-treated patients exclusively. It is unlikely that such a trial would ever be done.

Long-Term Antiplatelet Therapy
In each patient on warfarin, the indication for dual antiplatelet therapy should be judged at the moment of decision for stent implantation.

Because in general, the optimal duration of dual antiplatelet therapy in patients who have undergone stent implantation is still not fully established, the decision to continue or discontinue double antiplatelet therapy after stent implantation is and will be difficult. The only larger study available in this area is ZEST/REAL-LATE, in which patients stable 1 year after drug-eluting stent implantation were randomly assigned to continuation of clopidogrel plus aspirin or to aspirin alone.25 Nineteen months after discontinuation of clopidogrel, there was significantly more myocardial infarction, stroke, and death in the patients who had continued their clopidogrel treatment compared with those who stopped clopidogrel at random assignment 1 year after implantation. Currently, 2 megatrials are evaluating the optimal duration of dual antiplatelet therapy in stented patients. One is comparing 12 versus 30 months of dual antiplatelet therapy in 20 000 patients with bare metal or drug-eluting stents, using stent thrombosis, major bleeding, and major cardiovascular/cerebrovascular events as end points (the DAPT trial). The second study is the German ISAR-SAFE study, with 6000 patients with drug-eluting stents on dual antiplatelet therapy for 6 versus 12 months; the primary end point is death, stroke, and major bleeding at 15 months.

Conclusion
Dual antiplatelet therapy in patients undergoing stent implantation with additional oral anticoagulation increases bleeding risk. Among physicians, large differences in opinion exist about the duration of antiplatelet therapy in these cases: which agent to discontinue first and when? In the lack of results of randomized trials, expert opinion is needed. Both American and European leaders in the field have published their opinions on the optimal patient treatment; however, the American colleagues focus more on prevention of thrombotic events and the Europeans focus more on prevention of bleeding complications.

Disclosures
Dr Verheugt received educational and research grants from Bayer AG, Roche, Eli Lilly, and Boehringer Ingelheim and honoraria for consultancies/speaker fees from Daiichi-Sankyo, Eli Lilly, Merck, The Medicines Company, and Bayer AG.

References

Key Words: Editorials □ warfarin □ aspirin □ clopidogrel □ stent
Triple Antithrombotic Therapy After Coronary Stenting: Why Expert Opinion Is Necessary
Freek W.A. Verheugt

Circ Cardiovasc Interv. 2011;4:410-412
doi: 10.1161/CIRCINTERVENTIONS.111.965210
Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/4/5/410

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org//subscriptions/